lobbying_activities: 3053208

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3053208	48bf7db4-7129-4824-9060-760d422c1970	Q3	TRAVERE THERAPEUTICS	401104190	TRAVERE THERAPEUTICS	2023	third_quarter	MED	Legislation regarding FDA and clinical research, particularly with respect to rare disease and orphan drug development and the accelerated approval pathway, and related legislation regarding FY 2024 Appropriations. FY 2024 appropriations for CDC newborn screening resources.	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE		175000	0	0	2023-10-17T13:22:17-04:00